MDR study population: clinical and biologic characteristics of 203 ALL patients treated according to the ALL0496 protocol
| Characteristic . | No. . | Percentage . |
|---|---|---|
| Age (y) | ||
| ≤ 30 | 100 | 49.3 |
| 31-50 | 73 | 36.0 |
| 51-60 | 30 | 14.7 |
| Mean | 30 | — |
| Range | 14-59 | — |
| Sex | ||
| Male/female | 128/75 | 63.0/37.0 |
| WBC × 109/L | ||
| ≤ 10 | 75 | 37.0 |
| 11-50 | 62 | 30.5 |
| > 50 | 65 | 32.0 |
| Missing | 1 | 0.5 |
| Median | 21.6 | — |
| Range | 0.7-848.0 | — |
| Immunophenotype | ||
| B-ALL | 160/203 | 78.8 |
| T-ALL | 43/203 | 21.2 |
| Cytogenetics | ||
| Normal karyotype | 53/195 | 27.2 |
| Abnormal karyotype | 89/195 | 45.6 |
| Failure | 53/195 | 27.2 |
| Molecular genetics | ||
| BCR/ABL− | 148/199 | 74.4 |
| BCR/ABL+ | 51/199 | 25.6 |
| t(4;11)− | 169/182 | 92.9 |
| t(4;11)+ | 13/182 | 7.1 |
| Response to treatment | ||
| Complete remission | 148/200 | 74.0 |
| Resistance | 25/200 | 12.5 |
| Induction deaths | 25/200 | 12.5 |
| Off study | 2/200 | 1.0 |
| Relapse | 66/148 | 44.6 |
| Characteristic . | No. . | Percentage . |
|---|---|---|
| Age (y) | ||
| ≤ 30 | 100 | 49.3 |
| 31-50 | 73 | 36.0 |
| 51-60 | 30 | 14.7 |
| Mean | 30 | — |
| Range | 14-59 | — |
| Sex | ||
| Male/female | 128/75 | 63.0/37.0 |
| WBC × 109/L | ||
| ≤ 10 | 75 | 37.0 |
| 11-50 | 62 | 30.5 |
| > 50 | 65 | 32.0 |
| Missing | 1 | 0.5 |
| Median | 21.6 | — |
| Range | 0.7-848.0 | — |
| Immunophenotype | ||
| B-ALL | 160/203 | 78.8 |
| T-ALL | 43/203 | 21.2 |
| Cytogenetics | ||
| Normal karyotype | 53/195 | 27.2 |
| Abnormal karyotype | 89/195 | 45.6 |
| Failure | 53/195 | 27.2 |
| Molecular genetics | ||
| BCR/ABL− | 148/199 | 74.4 |
| BCR/ABL+ | 51/199 | 25.6 |
| t(4;11)− | 169/182 | 92.9 |
| t(4;11)+ | 13/182 | 7.1 |
| Response to treatment | ||
| Complete remission | 148/200 | 74.0 |
| Resistance | 25/200 | 12.5 |
| Induction deaths | 25/200 | 12.5 |
| Off study | 2/200 | 1.0 |
| Relapse | 66/148 | 44.6 |